### **KEY DEADLINES**

**15 February 2011** Submission of abstract

(including Forms A and B)

**15 February 2011** Submission of grant

applications (Forms A and C)

**15 May 2011** Notification of acceptance of

abstract

**15 August 2011** Submission of full paper

(only upon request by

the IAEA)

Any participant not submitting an abstract should submit Participation Form A through the appropriate authority as soon as possible (see conference web page for further details).

### PAPER SUBMISSION

The abstracts and full papers must be submitted to: ipet2011@iaea.org

### **REGISTRATION**

No registration fee is charged.

# LANGUAGE

The conference will be held in English.

## **CONTACT INFORMATION**

International Atomic Energy Agency Vienna International Centre

PO Box 100

1400 Vienna, Austria

Telephone No.: (+43 1) 26000

Fax No.: (+43 1) 26007 Email: official.mail@iaea.org

#### **CONFERENCE SECRETARIAT**

#### **Scientific Secretariat of the Conference**

Email: ipet2011@iaea.org

Fax: (+43 1) 26007

Mr M. Dondi

Tel.: (+43 1) 2600 21670

Ms D. Paez

Tel.: (+43 1) 2600 21678

Mr M. Haji-Saeid

Tel.: (+43 1) 2600 21748

Mr S. Palm

Tel.: (+43 1) 2600 21659


## **Administration and Organization**

Ms D. Umgeher Email: d.umgeher@iaea.org Tel.: (+43 1) 2600 21324

# Conference web page

http://www-pub.iaea.org/MTCD/Meetings/ Announcements.asp?ConflD=38296

Please include reference number IAEA-CN-185 in all communications.



### **BACKGROUND AND OBJECTIVES**

The first International Conference on Clinical PET and Molecular Nuclear Medicine (IPET 2007) was held in 2007 in Bangkok, Thailand, and attracted 286 participants from 76 Member States. Building on this, IPET 2011 will be held in Vienna and it is expected to have a major impact on the growing field of clinical PET, bringing together PET practitioners from developed and developing countries.

The main objectives of the conference are:

- To evaluate the current status of clinical PET, molecular nuclear medicine and related radiopharmacology, with emphasis on cancer;
- To reflect on the challenges of establishing PET in developing countries;
- To deliver supporting know-how via continuing medical education programmes in the rapidly growing field of molecular imaging;
- To improve the performance of clinical practice through read with experts sessions and workshops;
- physicians, radiologists, technologists, radiographers, radiopharmacists, radiochemists, medical physicists and other scientists working in all aspects of molecular nuclear medicine) and disseminate the most important information in the field;
- To exchange information on the current advances in the field among leading clinical scientists from developed and developing countries;
- To identify future challenges and directions.

### LIST OF TOPICS

Both academic and practice based papers in the following areas are welcomed:

- Member State experience with PET and recent applications in molecular nuclear medicine;
- Applications of PET and SPECT with emphasis on oncology, neurology, cardiology and infection;
- Cancer management and treatment planning with PET;
- Cyclotrons and generators for PET tracers;
- Radiopharmaceutical production, good manufacturing practices and quality assurance;
- PET in translational research;
- PET and SPECT physics, instrumentation and data analysis;
- Quality systems, quality control, quality assurance and audits in nuclear medicine practice;
- Radiation protection for personnel and dose reduction for patients in nuclear medicine practice;
- Training and education in PET and molecular nuclear medicine.

### PROGRAMME STRUCTURE

The scientific programme will comprise morning sessions on continuing medical education, covering selected topics of general interest to all participants. After lunch, breakout sessions for physicians, medical physicists, radiopharmacists/radiochemists and technologists will be conducted in parallel. Clinical topics will be addressed in main lectures and read with experts sessions; the Radiopharmacy and Physics and Instrumentation sessions will include workshops on selected topics.

### TARGET AUDIENCE

Professionals involved in the practice of nuclear medicine, including physicians, physicists, technologists/radiographers and radiopharmacists/radiochemists.

